Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh

More documents

Recommendations

Info

52 Room for notes.
Life Sciences Outlook 2012 Dutch biotech companies: from start-up to exit 53
Page 1: Life Sciences Outlook 2012 Dutch bi
Page 5 and 6: Table of contents. Preface 3 Introd
Page 7: will flow through the Netherlands O
Page 10 and 11: Academic institutes as the Petri di
Page 12 and 13: “You don’t start a biotech comp
Page 14 and 15: Best practice in life sciences tech
Page 16 and 17: The role of government “One thing
Page 19 and 20: 2. Investing. At the point that a s
Page 21 and 22: “We also have ourselves to blame,
Page 23 and 24: “Life sciences are far more diffi
Page 25: The evolving relationship between m
Page 28 and 29: A lack of ambition or healthy reali
Page 30 and 31: The term ‘strategic alliance’ i
Page 33 and 34: 4. Exit strategy. The last stage in
Page 35 and 36: In each case, a decision will have
Page 37 and 38: “IPOs are currently financing eve
Page 39 and 40: The technical IPO or even a hybrid
Page 41 and 42: However, the government could becom
Page 43 and 44: Galapagos NV: Onno van de Stolpe (C
Page 45 and 46: About Niaba. The Netherlands Biotec
Page 47 and 48: The Netherlands The Netherlands Joh
Page 49 and 50: The Netherlands Belgium Bart van Ke
Page 51: Disclaimer. This publication contai

Life Sciences Outlook 2012 Dutch biotech companies ... - NautaDutilh

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?